
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Malaysia Gives Nod to RaQualia’s Tegoprazan for Gastroesophageal Reflux Disease Treatment
Details : K-CAB (tegoprazan) is a potassium-competitive acid blocker (P-CAB), a new-generation acid suppressant. It is indicated for the treatment of gastroesophageal reflux disease.
Product Name : K-CAB
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 27, 2024
Lead Product(s) : Tegoprazan
Therapeutic Area : Gastroenterology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
